Brainstorm Cell had
Brainstorm Cell president
Brainstorm Cell has developed a stem cell treatment, NurOwn, for ALS, which passed its phase I clinical trial. The success of the study caused the company to bring forward the Phase IIa clinical trial (preliminary efficacy study), which had good interim results.
The company is also developing NurOwn for Parkinson's disease, and recently began examining the product for the treatment of autism. NurOwn is derived from autologous bone marrow-derived mesenchymal stem cells mixed with a proprietary cocktail that are injected back into the patient's damaged spine or muscles to excrete the substances to prevent inflammation, protect existing cells and encourage the regeneration of nerve cells in the damaged area.
(c)2014 the Globes (Tel Aviv, Israel)
Visit the Globes (Tel Aviv, Israel) at www.globes.co.il/serveen/globes/nodeview.asp?fid=942
Distributed by MCT Information Services